Half Year Report January - June 1999

Active Biotech Group Half Year Report January - June 1999 * SmithKline Beecham gives top priority to the ETEC-vaccine * completes Phase III trials in a new project organisation * Investing in increased production capacity for the ETEC-vaccine * The cholera vaccine - international breakthrough following WHO recommendation * SAIK-MS in Phase I - great market potential * Focusing and integration provide savings of approx. 75 MSEK a year * Pre-tax profit -74.9 MSEK, 20 MSEK better than plan * Shareholders' equity per share 93 SEK and available liquid funds per share 64 SEK * Group equity/assets ratio 75 % * Available liquid funds 721 MSEK ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/08/27/19990827BIT00420/bit0001.doc The full report http://www.bit.se/bitonline/1999/08/27/19990827BIT00420/bit0002.pdf The full report

About Us

Active Biotech's activity is in the biomedical area. The company focuses on R & D.